|
|
Article: Callisto CEO Video Spotlights Company's Drug Candidates to Treat Devastating Multiple Myeloma and Leukemia Blood Cancers; Drugs under Development as New Therapies for Patients Who Fail to Respond to Existing Treatments.
- Article from:
- Business Wire
- Article date:
- October 14, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4), a developer of new drug treatments in the fight against hematological cancers and related diseases, has announced the release of a corporate video that spotlights the Company's lead anti-cancer drug candidates, Atiprimod and Annamycin.
In the video, CEO Dr. Gary S. Jacob outlines Callisto's drug development programs and describes some of the key anticipated medical and marketplace advantages of the company's two drug candidates, Atiprimod and Annamycin, which are being developed as treatments for relapsed multiple myeloma and relapsed leukemia, respectively. Patients are referred to as "relapsed" ...